




RealRate

PHARMACEUTICAL 2020

Lipocine Inc.
Rank 254 of 358

LIPOCINE®
ENHANCING HEALTH





PHARMACEUTICAL 2020

Lipocine Inc.
Rank 254 of 358



The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Lipocine Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is -13%, being 50% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	19,631
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,965
Liabilities, Non-Current	3,814
Other Assets	24
Other Compr. Net Income	0.93
Other Expenses	0.20
Other Liabilities	4,591
Other Net Income	-107
Other Revenues	165
Property and Equipment	3.6
Research and Development	7,468
Selling, General and Administrative Expense	5,597

Output Variable	Value in 1000 USD
Assets	19,658
Liabilities	13,370
Expenses	13,065
Revenues	165
Stockholders Equity	6,288
Net Income	-13,007
Comprehensive Net Income	-13,007
Economic Capital Ratio	-13%